In contrast, PD-1/PD-L1 inhibitors act predominantly in peripheraltissues and within the tumor microenvironment, reversing T-cell exhaustion by blocking PD-1 on effector T cells or PD-L1 on tumor andstromal cells [7]. This evidence concerns the gene CD274 and neoplasm.